European Radiology:术前CT扫描有助于预测肝移植术后肝功能衰竭患者的预后

2022-02-10 shaosai MedSci原创

慢性肝病的严重急性失代偿,即有3个或更多器官衰竭的肝衰竭,称为慢加急性肝衰竭3级(ACLF3),是肝移植的指征之一。

慢性肝病的严重急性失代偿,即有3个或更多器官衰竭的肝衰竭,称为慢加急性肝衰竭3级(ACLF3),肝移植指征之一。为了改善对肝移植LT)患者的选择,学者提出了一些有关预后的临床和生物学参数以进行器官衰竭严重程度的评估,例如移植ACLF3模型或TAM评分,其中包括年龄、移植前呼吸衰竭、动脉乳酸水平和白细胞计数。

现阶段,影像学可以通过容积评估进行肝脏功能的评估,并通过脾脏容积测定和半定量评估门静脉分流来评估门静脉高压的严重程度。然而,在ACLF3的特殊临床情况下,尚未由关于影像参数进行预后评估的全面研究。

近日,发表在European Radiology杂志的一项研究在最大的单中心经验中确定与LT后1年生存率相关的形态学参数,为临床更好地识别无效LT患者提供了参考,并进一步完善现有的临床-生物学评分标准

本研究回顾性地纳入2010年1月至2020年1月期间接受肝移植的3级ACLF患者,并在LT前3个月进行对比增强腹部计算机断层扫描(CT)。主要终点是1年的死亡率。对影像学参数(肌肉疏松症、肝脏形态和体积,以及门静脉高压的迹象)进行了筛选和测试,以建立一个预后评分。 

在多变量分析中,发现三个独立的CT预后因素:脾脏肿大(p = 0.021;HR = 5.6(1.29-24.1))、肝脏萎缩(p = 0.05;HR = 2.93(1.01-10.64))和腔静脉直径比(p < 0.0001;HR = 12.7(3.4-92))。根据存在脾脏肿大(5分)、肝脏萎缩(5分)和腔静脉直径比<0.2(12分),提出了一个简单的预后评分。10分的分界线将高危组(得分>10)与低危组(得分≤10)区分开来,1年生存率分别为27%和67%(P <0.001)。该预后评分是一个独立的预测因素,与ACLF3模型的移植(TAM)分相关。 

 

 VCR测量的示例子。左图是肾上(a)和肾下(b)静脉血管直径的轴位层面位置。中图为VCR=0.30的患者的测量结果。右图是另一位VCR=0.14的患者的测量结果。

本研究表明包括移植前腹部CT的3个形态学参数的简单评分可以预测ACLF3患者移植后1年的死亡率,对临床生物评分(如TAM评分)有明显的附加价值,特别是对预后情况明确的患者来说更为显著

原文出处

Antoine Wackenthaler,Sébastien Molière,Thierry Artzner,et al.Pre-operative CT scan helps predict outcome after liver transplantation for acute-on-chronic grade 3 liver failure.DOI:10.1007/s00330-021-08131-1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999016, encodeId=4b391999016d7, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 30 23:10:36 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944892, encodeId=542a19448925d, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Fri Oct 07 15:10:36 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729340, encodeId=c5021e293403d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 20 22:10:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366757, encodeId=c6541366e57f8, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618781, encodeId=ae221618e81c2, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-03-30 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999016, encodeId=4b391999016d7, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 30 23:10:36 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944892, encodeId=542a19448925d, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Fri Oct 07 15:10:36 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729340, encodeId=c5021e293403d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 20 22:10:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366757, encodeId=c6541366e57f8, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618781, encodeId=ae221618e81c2, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999016, encodeId=4b391999016d7, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 30 23:10:36 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944892, encodeId=542a19448925d, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Fri Oct 07 15:10:36 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729340, encodeId=c5021e293403d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 20 22:10:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366757, encodeId=c6541366e57f8, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618781, encodeId=ae221618e81c2, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-09-20 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999016, encodeId=4b391999016d7, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 30 23:10:36 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944892, encodeId=542a19448925d, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Fri Oct 07 15:10:36 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729340, encodeId=c5021e293403d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 20 22:10:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366757, encodeId=c6541366e57f8, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618781, encodeId=ae221618e81c2, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999016, encodeId=4b391999016d7, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 30 23:10:36 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944892, encodeId=542a19448925d, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Fri Oct 07 15:10:36 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729340, encodeId=c5021e293403d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Sep 20 22:10:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366757, encodeId=c6541366e57f8, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618781, encodeId=ae221618e81c2, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Feb 12 01:10:36 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

相关资讯

Hepatology:肝脏硬度可预测癌症、肝功能衰竭及死亡率

近日,来自西班牙的研究者表示,通过瞬时弹性成像(TE)的方法确定的肝脏硬度是肝功能衰竭、肝细胞癌(HCC)以及HIV、HCV相关的疾病死亡的重要预测标准。相关研究成果刊登在了7月份的国际杂志Hepatology上。 据WHO数据,慢性HCV(慢性丙肝)在世界范围内影响着超过1.7亿人的健康,而且每年超过350,000病人因为HCV相关的疾病而死亡。WHO报告说,2010年有3400万感染了HIV

Eur Radiol:脾脏体积还能与肝细胞癌切除术后肝功能衰竭以及术后总生存率有关系?

根据主要的国际HCC管理指南,肝纤维化或肝硬化与门脉高压密切相关,门脉高压的存在是HR的禁忌症。随着门脉高压的进展,纤维化以及门脉系统充血进一步加重,脾静脉回流受

Liver Transpl:急性肝功能衰竭患者:低温治疗

Figure1. Twenty-one–day spontaneous survival percentages (unadjusted) for 1232 ALF patients with grade III/IV HE. All patients included controls (1135) and TH patients (97; P=0.24).APAP patients inc